SCHEMBL16627316

SCHEMBL16627316

CC(C)(C)[Si](OC1CN(Cc2ccc(C#N)cc2F)C1)(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.41
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
CHRM4 P08173 1/20 0.36
DRD2 P14416 6/20 0.36
DRD3 P35462 6/20 0.36
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
CHRM2 P08172 1/20 0.34
KCNH2 Q12809 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
GLP1R P43220 2/20 0.33
DRD4 P21917 2/20 0.33
S1PR1 P21453 1/20 0.33
PRKX P51817 1/20 0.33
IKBKE Q14164 1/20 0.33
S1PR5 Q9H228 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16627300 0.83 HRH3 (0.46) BACE1DRD2DRD3DRD4ALDH1A1
SCHEMBL15647859 0.73 BCHE (0.39) BACE1DRD2
SCHEMBL18156517 0.72 HRH3 (0.58) BACE1CHRM4DRD4
SCHEMBL16625286 0.72 TNKS (0.47)
SCHEMBL16579005 0.71 DPP4 (0.42) BACE1KCNH2NAAA
SCHEMBL22084353 0.70 CHRM4 (0.45) JAK2JAK1TYK2JAK3CHRM4
SCHEMBL15271685 0.70 RORC (0.41) BACE1DRD4S1PR1S1PR5ALDH1A1
SCHEMBL31057273 0.69 MAPK1 (0.39) BACE1ALDH1A1
SCHEMBL29307379 0.69 SMYD2 (0.34) BACE1
SCHEMBL22283610 0.67 BACE1 (0.33) BACE1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2822656-B1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE CANCER RES INST ROYAL (GB) 2016-10-19 EP disclosed
US-9193689-B2 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-11-24 US disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE TNKS, TNKS2, PARP11 BACE1 911/4885JAK2 752/4885JAK1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.